Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study

Table 3 Distribution of patients in relation to the target range of linezolid

	Number (percentage) of linezolid patients
Patient groups, number of patients	AUC₂₄, mg*h/L^a			C_min, mg/L^b
Patient groups, number of patients	<200	200 to 400	>400	<2	2 to 10	>10
Total patients, n =30	19 (63)	9 (30)	2 (7)	15 (50)	13 (43)	2 (7)
Male patients, n = 20^c	13 (65)	5 (25)	2 (10)	11 (55)	7 (35)	2 (10)
Female patients, n = 10	6 (60)	4 (40)		4 (40)	6 (60)
On CRRT, n = 5^d	2 (40)	1 (20)	2 (40)		3 (60)	2 (40)
Not on CRRT, n = 25	17 (68)	8 (32)		15 (60)	10 (40)
On ECLA, n = 7^c	5 (71)	2 (29)		5 (71)	2 (29)
Not on ECLA, n = 23	14 (61)	7 (30)	2 (9)	10 (43)	11 (48)	2 (9)
After liver transplantation, n = 5^f	2 (40)	1 (20)	2 (40)		3 (60)	2 (40)
After lung transplantation, n = 10^c	6 (60)	4 (40)		6 (60)	4 (40)
No transplantation, n = 15	11 (73)	4 (27)		9 (60)	6 (40)

^aAs determined by the NONMEM system, values from the start of the third administration of linezolid; ^bas determined by liquid chromatography tandem mass spectrometry, values obtained directly before the fourth administration of linezolid; ^cno significantly different values in comparison to the corresponding patient group; ^dsignificantly higher values in patients on CRRT than in those not on CRRT (P <0.01); ^fsignificantly higher values in patients with liver transplantation than in non-liver-transplant patients (P <0.05). AUC₂₄, concentration time curve over 24 h; C_min, linezolid trough level; CRRT, continuous renal replacement therapy; ECLA, extracorporeal lung assist.

ISSN: 1364-8535